SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

NIO, Inc. is a holding company which engages in the design, manufacture, and sale of electric vehicles. Its products include the EP9 supercar and ES8 7-seater SUV. It provides users with home charging, power express valet services, and other power solutions including access to public charging, access to power mobile charging trucks, and battery swapping. It also offers other value-added services such as service package, battery payment arrangement, and vehicle financing and license plate registration. The company was founded by Bin Li and Li Hong Qin on November 28, 2014 and is headquartered in Jiading, China.

NIO Inc - ADR

NIO Inc

NIO is trending due to reported record-high monthly and quarterly delivery numbers, sparking enthusiasm about the company's growth. Community discussions revolve around the significant year-over-year increase in deliveries and the potential impact of new models like Onvo and Firefly. Some investors express optimism about NIO's future, while others focus on its valuation relative to competitors in the EV sector.

A project grown out of the community's love and passion for the weed culture. Launched around early 2025, $weedcoin, “Like Bitcoin but way higher,” emphasizes its alignment with cannabis culture and a laid-back vibe. Unlike other Weed communities, this project leans heavily into community engagement over technical utility, aiming to build a “stoner community” through social media presence and decentralized governance. We also aim to focus on onboarding web2 businesses and users onto web3 through the token.

Weedcoin

Weedcoin is trending as the community rallies around the token's vision of merging cryptocurrency with green culture, emphasizing growth, freedom, and innovation within the digital space. Discussions highlight Weedcoin as more than just a digital currency, but as a symbol of a cultural movement and a key to unlocking future opportunities. The community expresses strong conviction and promotes Weedcoin as a force that shapes the digital landscape.

Lithium Americas Corp. engages in the development of the Thacker Pass project. It is focused on advancing Thacker Pass to production it is located in northern Nevada. The company was founded on January 23, 2023 and is headquartered in Vancouver, Canada.

Lithium Americas Corp (NewCo)

Lithium Americas Corp

Lithium Americas ($LAC) is trending after reports of a U.S. government equity stake, signaling strong support for domestic lithium production. The community is buzzing about a potential short squeeze and the stock's long-term prospects, drawing comparisons to government-backed runs of $MP and $INTC. Investors view this as a bullish sign for the company's Thacker Pass project and its role in securing the U.S. lithium supply chain.

SSgA Active Trust - SPDR S&P 500 ETF Trust

The SPY is trending as a government shutdown looms, triggering volatility and uncertainty. Community members are debating whether the shutdown is already priced in, with some anticipating a potential dip while others expect a market rally similar to past shutdowns. Overall sentiment is mixed, with both bullish and bearish arguments circulating, focusing on historical patterns and potential economic impacts.

Uniting the six native Japanese dog breeds. Kendu is the keeper of peace, the preserver of life, and the protector of unity. Join the pack!!

Kendu

Kendu.X is trending as the community rallies around its strong IRL presence and expanding ecosystem, including Kendu Energy drink and other branded products.  Enthusiasm is high as the holder count approaches 19,000, with community members emphasizing that the project combines a high degree of decentralization with a high share of diamond hand holders and a tireless work ethic.

Aventus Network

Aventus Network ($AVT.X) is trending due to its strong chart setup, real-world partnerships (Vodafone, Heathrow Airport, Polkadot) and potential for a breakout. Community members believe the token is undervalued, highlighting its low market cap and integration with Polkadot as catalysts for significant upside. Traders are closely monitoring volume as a key indicator for potential price movement.

NIKE, Inc. engages in the design, development, marketing, and sale of athletic footwear, apparel, accessories, equipment, and services. It operates through the following segments: North America, Europe, Middle East, and Africa (EMEA), Greater China, Asia Pacific and Latin America (APLA), Global Brand Divisions, Converse, and Corporate. The North America, EMEA, Greater China, and APLA segments refer to the design, development, marketing, and selling of athletic footwear, apparel, and equipment. The Global Brand Divisions segment represents its NIKE Brand licensing businesses. The Converse segment designs, markets, licenses, and sells casual sneakers, apparel, and accessories. The Corporate segment is composed of unallocated general and administrative expenses. The company was founded by William Jay Bowerman and Philip Hampson Knight on January 25, 1964 and is headquartered in Beaverton, OR.

Nike, Inc. - Ordinary Shares - Class B

Nike Inc

Nike is trending as investors react to earnings, with community chatter focused on revenue growth and turnaround efforts despite tariff concerns. Discussions include both bullish and bearish outlooks, with some anticipating a move towards $80 while others foresee a drop. The brand's collaboration with SKIMS and the impact of global factors like China sales and potential government shutdowns are also being closely monitored.

Top Wealth Group Holding Ltd. operates as a holding company, which provides caviar and caviar-based gourmet products. It focuses on supplying sturgeon caviar to customers under its own brand, Imperial Cristal Caviar. The company was founded by Kim Kwan Kings Wong on February 1, 2023 and is headquartered in Hong Kong.

Top Wealth Group Holding Ltd. - Ordinary Shares - Class A

Top Wealth Group Holding Ltd.

TWG is trending due to recent unaudited financial results showing positive EPS, sparking discussions about its low float and potential for a short squeeze. The community is actively watching key resistance levels and anticipating further upward movement. Some traders highlight the possibility of a share offering and caution around the stock's historical volatility and association with Chinese companies.

Invesco Capital Management LLC - Invesco QQQ Trust Series 1

QQQ is trending as the possibility of a government shutdown looms, creating market uncertainty. The community is debating the potential impact, with some anticipating a pullback while others believe a deal will be reached, leading to a rally. Discussions also involve broader market dynamics, such as the influence of a few mega-cap stocks and end-of-quarter window dressing.

Mannatech, Inc. engages in the development of nutritional supplements, topical and skin care products and weight-management products that target optimal health and wellness. Its product category includes integrative health, targeted health, wealth and fitness, skin care, essentials, and home. The company was founded by Marlin Ray Robbins and Samuel L. Caster in November 1993 and is headquartered in Flower Mound, TX.

Mannatech Inc

MTEX is trending due to recent price movement, with community members actively discussing potential breakouts and short squeezes, given the stock's low float. Traders are watching key resistance levels, anticipating further upward momentum if these levels are breached. Some traders are expressing concern over potential pump and dump.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

IO Biotech (IOBT) stock slumped 77% by Monday afternoon after the company announced that the U.S. Food and Drug Administration (FDA) recommended that the firm conduct another trial before submitting Cylembio for approval.IO Biotech held a meeting with the agency, which recommended that the firm not submit an application based on data from the IOB-013 clinical trial, in which Cylembio plus Merck’s Pembrolizumab improved progression-free survival (PFS), but narrowly missed statistical significance.“We look forward to continuing the dialogue with FDA to align on the design for a potential new registrational study. Additionally, we plan to discuss the data from our IOB-013 study with European regulators and determine a path to submission in the EU,” CEO Mai-Britt Zocca <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://investors.iobiotech.com/news-events/news/news-details/2025/IO-Biotech-Provides-Update-Following-Pre-BLA-Meeting-with-FDA/default.aspx">said</a>.The company also stated that it is implementing a plan to conserve capital while seeking approval for the drug and conducting ongoing studies. IO Biotech currently has capital to sustain its operation into the first quarter of 2026. However, it is now planning restructuring, including a halving of its workforce.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/IOBT">IOBT stock</a> jumped from ‘neutral’ to ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘normal’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:577/60;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_29_at_2_10_50_PM_png_0d2cc62fff.webp" alt="IOBT's Sentiment Meter and Message Volume as of 2:11 p.m. ET on Sept. 29, 2025 | Source: Stocktwits" width="577" height="60"><figcaption>IOBT's Sentiment Meter and Message Volume as of 2:11 p.m. ET on Sept. 29, 2025 | Source: Stocktwits</figcaption></figure>Following the company’s announcement, H.C. Wainwright downgraded IO Biotech to ‘Neutral’ from ‘Buy’ with no price target, as per TheFly. Given its cash position, the company would either need to raise additional capital, partner, or license out Cylembio to advance the new trial, the analyst noted.IO Biotech had <a href="https://stocktwits.com/news-articles/markets/equity/io-biotech-trial-of-cancer-therapy-plus-keytruda-misses-study-goal/chrHGKVRdeB">announced</a> in August that the late-stage trial of its investigational and therapeutic cancer vaccine, Cylembio, in combination with Pembrolizumab, failed to achieve statistical significance in terms of progression-free survival improvement compared to Keytruda alone.The trial evaluated Cylembio in combination with Keytruda versus Keytruda alone in 407 patients with previously untreated, unresectable, or metastatic (advanced) melanoma. Patients in the study treated with Cylembio in combination with Keytruda achieved a median progression-free survival of 19.4 months, compared to 11.0 months in patients treated with Keytruda alone. Progression-free survival (PFS) refers to the duration of time during and after cancer treatment during which a patient lives without the disease worsening.IOBT stock is down 61% this year and approximately 66% over the past 12 months.Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/enanta-pharmaceuticals-stock-rises-despite-rsv-treatment-mid-stage-trial-failing-main-goal/chDuJaER3JS">Enanta Pharmaceuticals Stock Rises 58% – Here’s An Important Update</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Stock market down on a black background. | Image source: Yuichiro Chino via Getty Images

IO Biotech Stock Plunges After FDA Recommends Another Trial For Investigational Cancer Vaccine

Following the announcement, H.C. Wainwright downgraded IO Biotech to ‘Neutral’ from ‘Buy’ with no price target. 

Equity

Following the announcement, H.C. Wainwright downgraded IO Biotech to ‘Neutral’ from ‘Buy’ with no price target. 


IO Biotech, Inc. (IOBT) Upgraded to Buy: Here's What You Should Know

IO Biotech, Inc. (IOBT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

IO Biotech (IOBT) announced on Monday that its investigational and therapeutic cancer vaccine, Cylembio, in combination with Merck’s (MRK) Keytruda, failed to achieve statistical significance in progression-free survival improvement in a late-stage trial compared to Keytruda alone.IOBT stock traded over 19% lower on Monday morning, at the time of writing. The company <a target="_blank" rel="noopener noreferrer nofollow" href="https://iobiotech.com/press-releases/?workflow=6562e614-30a0-4300-9a37-ab75253933a2">said</a> Cylembio plus Keytruda demonstrated clinical improvement in progression-free survival compared to Keytruda alone, but statistical significance was “narrowly” missed. Improvement in progression-free survival was achieved across virtually all subgroups, including those with poor prognostic factors, the company said.The trial evaluated Cylembio in combination with Keytruda versus Keytruda alone in 407 patients with previously untreated, unresectable, or metastatic (advanced) melanoma. Patients in the study treated with Cylembio in combination with Keytruda achieved 19.4 months of median progression-free survival compared to 11.0 months in patients treated with Keytruda alone. Progression-free survival (PFS) refers to the length of time during and after cancer treatment that a patient lives without the disease worsening.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/IOBT">IOBT</a> jumped from ‘neutral’ to ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘normal’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:625/61;" src="https://news.stocktwits-cdn.com/Screenshot_2025_08_11_at_9_43_00_AM_png_243b1797b9.webp" alt="IOBT's Sentiment Meter and Message Volume as of 9:43 a.m. ET on Aug. 11, 2025 | Source: Stocktwits" width="625" height="61"><figcaption>IOBT's Sentiment Meter and Message Volume as of 9:43 a.m. ET on Aug. 11, 2025 | Source: Stocktwits</figcaption></figure> A Stocktwits user expressed optimism about the data.<stembedurl>https://stocktwits.com/Notnotshort/message/624573071</stembedurl>Another opined that the stock price should multiply by 10 times in the aftermath of the data release.<stembedurl>https://stocktwits.com/Abo_Hamza/message/624572510</stembedurl>A trend toward an improvement in overall survival was also observed in the study, though data is not yet mature, the company said. Overall survival (OS) is a key metric in clinical trials, particularly for cancer, representing the length of time from a specific event (like diagnosis or treatment start) that patients remain alive.“The magnitude and durability of clinical effect observed consistently across subgroups supports our confidence in Cylembio and its potential as a treatment for advanced melanoma patients. We look forward to engaging with the FDA to determine a potential path to approval based on these data,” said Mai-Britt Zocca, CEO of IO Biotech.IO Biotech plans to meet with the U.S. Food and Drug Administration (FDA) this fall to discuss the data and determine next steps for submission of a Biologics License Application (BLA) for the treatment of advanced melanoma.IOBT stock is up by 59% this year and by about 12% over the past 12 months.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/kroger-reaches-settlement-with-c-and-s-wholesale-grocers/chruzkSRdec">Big News On Kroger! Company Reaches Settlement With C&amp;S Wholesale Grocers</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

IO Biotech Stock Slumps After Trial Of Cancer Therapy Plus Keytruda Misses Study Goal: Retail Sees Shares Rise 10x

The company said Cylembio plus Keytruda demonstrated clinical improvement in progression-free survival compared to Keytruda alone, but statistical significance was “narrowly” missed.

IO Biotech, Inc. (IOBT) Just Flashed Golden Cross Signal: Do You Buy?

Analysts Offer Insights on Healthcare Companies: BioMarin Pharmaceutical (BMRN) and IO Biotech (IOBT)

There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on BioMarin Pharmaceutical (BMRN Research Report) and IO Biotech...

IO Biotech's Promising Phase 3 Cancer Vaccine Trial Advances

The latest announcement is out from IO Biotech (IOBT). On August 30, 2024, the Company revealed positive news from its Phase 3 trial of the cancer...

IO Biotech appoints Faical Miyara as CBO

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

IO Biotech Appoints Fai al Miyara, Ph.D., as Chief Business Officer

NEW YORK, April 05, 2024 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating therapeutic cancer vaccines based on its T-win...

IO Biotech, Inc. (NASDAQ:IOBT) Sees Large Growth in Short Interest

IO Biotech, Inc. (NASDAQ:IOBT - Get Free Report) was the target of a large growth in short interest during the month of March. As of March 15th, there was short interest totalling 81,600 shares, a...

Comparing IO Biotech (NASDAQ:IOBT) and Evotec (OTCMKTS:EVTCY)

Evotec (OTCMKTS:EVTCY  Get Free Report) and IO Biotech (NASDAQ:IOBT  Get Free Report) are both medical companies, but which is the better stock? We will compare the two businesses based...

IO Biotech, Inc. engages in the development of immune modulating cancer therapies based on its T-win technology platform. Its platform is a novel approach to cancer immunotherapy designed to activate naturally occurring T cells to target immunosuppressive mechanisms. The company was founded by Mai-Britt Zocca, Inge Marie Svane, and Mads Hald Andersen in December 2014 and is headquartered in Copenhagen, Denmark.

IO Biotech Inc

0 to 25,000

25,000 to 50,000

50,000 to 75,000

75,000 to 100,000

How many jobs did the U.S. add in September? Vote below + drop your exact prediction in the comments. 
 
*Powered by Polymarket

IOBT
IO Biotech Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest IOBT News

IOBT IO Biotech Inc